{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:24Z","timestamp":1794047364902,"version":"4.8.0"},"reference-count":16,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Emapalumab, a fully human anti-IFN\u03b3 monoclonal antibody, has been approved in the US as second-line treatment of primary hemophagocytic lymphohistiocytosis (HLH) patients and has shown promise in patients with graft failure (GF) requiring a second allogeneic hematopoietic stem cell transplantation (HSCT). The blockade of IFN\u03b3 activity may increase the risk of severe infections, including fatal mycobacteriosis. We report a case of secondary HLH-related GF in the context of HLA-haploidentical HSCT successfully treated with emapalumab in the presence of concomitant life-threatening infections, including disseminated tuberculosis (TB). A 4 years old girl with Adenosine Deaminase-Severe Combined Immunodeficiency complicated by disseminated TB came to our attention for ex-vivo hematopoietic stem cell-gene therapy. After engraftment failure of gene corrected cells, she received two HLA-haploidentical T-cell depleted HSCT from the father, both failed due to GF related to concomitant multiple infections and secondary HLH. Emapalumab administration allowed to control HLH, as well as to prevent GF after a third haplo-HSCT from the mother. Remarkably, all infections improved with antimicrobial medications and disseminated TB did not show any reactivation. This seminal case supports emapalumab use for treatment of secondary HLH and prevention of GF in patients undergoing haplo-HSCT even in the presence of multiple infections, including TB.<\/jats:p>","DOI":"10.3324\/haematol.2020.255620","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T09:55:33Z","timestamp":1597312533000},"page":"641-646","source":"Crossref","is-referenced-by-count":17,"title":["Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis- related graft failure and disseminated bacillus Calmette-Gu\u00e9rin infection"],"prefix":"10.3324","volume":"106","author":[{"family":"Francesca Tucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Vera Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Federica Barzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Francesca Ferrua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maddalena Migliavacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Valeria Calbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Matteo Doglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Elena Sophia Fratini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Zeynep Karakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sukru Guner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Matilde Zambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Cristina Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Raffaella Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Salvatore Gattillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Benedetta Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Chiara Oltolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maurizio Barbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Cristina Baldoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Daniela Maria Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Veronica Asnaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Cristina De Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maria Pia Cicalese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Fabio Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alessandro Aiuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maria Ester Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"20875","doi-asserted-by":"crossref","unstructured":"Al-Salama ZT. Emapalumab: first global approval. Drugs. 2019; 79(1):99-103.","DOI":"10.1007\/s40265-018-1046-8"},{"key":"20876","doi-asserted-by":"crossref","unstructured":"Locatelli F, Jordan MB, Allen C. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020; 382(19):1811-1822.","DOI":"10.1056\/NEJMoa1911326"},{"key":"20877","doi-asserted-by":"crossref","unstructured":"Merli P, Caruana I, De Vito R. Role of interferon-\u03b3 in immunemediated graft failure after allogeneic hematopoietic stem cell transplantation. Haematologica. 2019; 104(11):2314-2323.","DOI":"10.3324\/haematol.2019.216101"},{"key":"20878","doi-asserted-by":"crossref","unstructured":"Dorman SE, Picard C, Lammas D. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet. 2004; 364(9451):2113-2121.","DOI":"10.1016\/S0140-6736(04)17552-1"},{"key":"20879","doi-asserted-by":"crossref","unstructured":"Lammas DA, Casanova JL, Kumararatne DS. Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-\u03b3) pathway. Clin Exp Immunol. 2000; 121(3):417-425.","DOI":"10.1046\/j.1365-2249.2000.01284.x"},{"key":"20880","doi-asserted-by":"crossref","unstructured":"Kohn DB, Hershfield MS, Puck JM. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol. 2019; 143(3):852-863.","DOI":"10.1016\/j.jaci.2018.08.024"},{"key":"20881","doi-asserted-by":"crossref","unstructured":"Bertaina A, Merli P, Rutella S. HLA-haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders. Blood. 2014; 124(5):822-826.","DOI":"10.1182\/blood-2014-03-563817"},{"key":"20882","doi-asserted-by":"crossref","unstructured":"Henter JI, Horne A, Aric\u00f2 M. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48(2):124-131.","DOI":"10.1002\/pbc.21039"},{"key":"20883","doi-asserted-by":"crossref","unstructured":"Sauer AV, Mrak E, Jofra Hernandez R. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL\/OPG imbalance and osteoblast insufficiency. Blood. 2009; 114(15):3216-3226.","DOI":"10.1182\/blood-2009-03-209221"},{"key":"20884","doi-asserted-by":"crossref","unstructured":"Zhang SY, Boisson-Dupuis S, Chapgier A. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-\u03b1\/\u03b2, IFN-\u03b3, and IFN-l in host defense. Immunol Rev. 2008; 226:29-40.","DOI":"10.1111\/j.1600-065X.2008.00698.x"},{"key":"20885","doi-asserted-by":"crossref","unstructured":"Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004; 104(3):735-743.","DOI":"10.1182\/blood-2003-10-3413"},{"key":"20886","doi-asserted-by":"crossref","unstructured":"Locatelli F, Jordan MB, Allen CE. Safety and efficacy of emapalumab in pediatric patients with primary hemophagocytic lymphohistiocytosis. Blood. 2018; 132(Suppl 1):LBA-6.","DOI":"10.1182\/blood-2018-120810"},{"key":"20887","doi-asserted-by":"crossref","unstructured":"De Benedetti F, Brogan P, Grom P. Emapalumab, an interferon gamma (IFN\u03b3) blocking monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA). Ann Rheum Dis. 2019; 78(Suppl 2):178.","DOI":"10.1136\/annrheumdis-2019-eular.3341"},{"key":"20888","doi-asserted-by":"crossref","unstructured":"Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019; 3(1):47-50.","DOI":"10.1182\/bloodadvances.2018025858"},{"key":"20889","doi-asserted-by":"crossref","unstructured":"Prencipe G, Caiello I, Pascarella A. Neutralization of IFN-\u03b3 reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2018; 141(4):1439-1449.","DOI":"10.1016\/j.jaci.2017.07.021"},{"key":"20890","doi-asserted-by":"crossref","unstructured":"Buatois V, Chatel L, Cons L. Use of a mouse model to identify a blood biomarker for IFN\u03b3 activity in pediatric secondary hemophagocytic lymphohistiocytosis. Transl Res. 2017; 180:37-52.","DOI":"10.1016\/j.trsl.2016.07.023"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9911\/71487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9911\/71488","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9911\/71487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:58Z","timestamp":1794045478000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.255620","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,13]]}}}